AXSOME THERAPEUTICS
(NASDAQ: AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies for the management of pain and other central nervous system (CNS) disorders. The Company's product, AXS-02 is an oral, targeted and non-opioid therapeutic for chronic pain. It is developing AXS-02 for the treatment of pain in three conditions: complex regional pain syndrome (CRPS); knee osteoarthritis associated with bone marrow lesions (BMLs); and chronic low back pain (CLBP), associated with type 1 or mixed type 1 and type 2 Modic changes (MCs). Its AXS-05 is a fixed-dose combination of dextromethorphan (DM) and bupropion. It is developing AXS-05 for the treatment of two conditions: treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD). Its AXS-05 has completed Phase II trials. The Company also have one active program, AXS-06, in preclinical development, which is developed for the treatment of chronic pain disorders.

98.015

-0.175 (-0.18%)
Range 97.640 - 99.300   (1.70%)
Open 98.990
Previous Close 98.190
Bid Price 69.090
Bid Volume 10
Ask Price 69.280
Ask Volume 8
Volume 103,012
Value -
Remark
Delayed prices. Updated at 23 Nov 2024 01:13.
Data powered by
View All Events

About AXSOME THERAPEUTICS INC

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies for the management of pain and other central nervous system (CNS) disorders. The Company's product, AXS-02 is an oral, targeted and non-opioid therapeutic for chronic pain. It is developing AXS-02 for the treatment of pain in three conditions: complex regional pain syndrome (CRPS); knee osteoarthritis associated with bone marrow lesions (BMLs); and chronic low back pain (CLBP), associated with type 1 or mixed type 1 and type 2 Modic changes (MCs). Its AXS-05 is a fixed-dose combination of dextromethorphan (DM) and bupropion. It is developing AXS-05 for the treatment of two conditions: treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD). Its AXS-05 has completed Phase II trials. The Company also have one active program, AXS-06, in preclinical development, which is developed for the treatment of chronic pain disorders.

Loading Chart...

Please login to view stock data and analysis